The impact of Aβ deposition upon cholinergic intrinsic cortical and striatal, as well as basal forebrain long projection neuronal systems was qualitatively and quantitatively evaluated in young (2-6 months) and middle-aged (10-16 months) APPswe/PS1ΔE9 transgenic (tg) mice. Cholinergic neuritic swellings occurred as early as 2-3 months of age in the cortex and hippocampus and 5-6 months in the striatum of tg mice. However, cholinergic neuron number or choline acetyltransferase (ChAT) optical density measurements remained unchanged in the forebrain structures with age in APPswe/PS1ΔE9 tg mice. ChAT enzyme activity decreased significantly in the cortex and hippocampus of middle-aged tg mice. These results suggest that Aβ deposition has age-dependent effects on cortical and hippocampal ChAT fiber networks and enzyme activity, but does not impact the survival of cholinergic intrinsic or long projection forebrain neurons in APPswe/ PS1ΔE9 tg mice.
Introduction
Alzheimer's disease (AD) is characterized by cognitive decline, which is accompanied by beta-amyloid (Aβ) plaque and neurofibrillary tangle formation in the diseased brain (Arnold et al., 1991; Braak and Braak, 1991) . In early onset familial forms of AD (FAD) and in sporadic AD Aβ-deposits are composed of ∼ 4 kDa Aβ-peptides derived from amyloid precursor proteins (APP). FAD are autosomal dominant forms of AD caused by the expression of mutant human genes encoding APP, presenilin 1 (PS1) or presenilin 2 (PS2), that lead to increased production of highly pathogenic 42-amino-acid β-amyloid (Aβ 1-42 ) peptides (Price and Sisodia, 1998) . In addition to plaque and tangle formation there is a reduction in subcortical cholinergic nucleus basalis neurons as well as cortical acetylcholine in AD (Davies and Maloney, 1976; Davies, 1979; Richter et al., 1980; Whitehouse et al., 1981 Whitehouse et al., , 1985 Mufson et al., 1989a,b; DeKosky et al., 2002) . Likewise, cholinergic interneurons and metabolic markers are reduced in the striatum in the presence of Aβ and neurofibrillary tangles in AD (Davies, 1979; Oyanagi et al., 1989; Braak and Braak, 1990; Selden et al., 1994a,b; Scott et al., 1995; Boissiere et al., 1997; Klunk et al., 2004) . Although Aβ aggregates/deposits are thought to be neurotoxic (Hartley et al., 1999; Selkoe, 2001) , perhaps by spreading from the cortex to subcortical nuclei (Saper et al., 1987; Mufson et al., 1995; Yanker, 1996) , the impact Aβ upon central cholinergic neuron degeneration in AD remains unclear.
Various types of transgenic mice have been engineered to mimic different aspects of AD neurodegeneration (Suh and Checler, 2002; Oddo et al., 2003; Götz et al., 2004) . In terms of cholinergic pathology, most mice over-expressing mutant APP and/or PS1 genes display an age-dependent Aβ deposition, cortical and hippocampal cholinergic fiber degeneration (Wong et al., 1999; Hernandez et al., 2001; Jaffar et al., 2001; Boncristiano et al., 2002; Buttini et al., 2002; German et al., 2003; Aucoin et al., 2005) and memory deficits (see Suh and Checler, 2002) . However, these changes are not accompanied by a loss of cholinergic basal forebrain neurons (Hernandez et al., 2001; Jaffar et al., 2001; Boncristiano et al., 2002; German et al., 2003) . Therefore, none of these mutant mice fully recapitulates the robust cholinergic neurodegeneration seen as one of the hallmarks of human AD. It is interesting to note that the majority of studies reporting cholinergic pathologies were performed in single APP or PS1 mutant mice, which have limited or no Aβ deposition (Hernandez et al., 2001; Jaffar et al., 2001; Boncristiano et al., 2002; Buttini et al., 2002; German et al., 2003; Aucoin et al., 2005; Bales et al., 2006) compared to APP/PS1 double transgenic mice (Wong et al., 1999; Hernandez et al., 2001; Jaffar et al., 2001) . Moreover, Aβ 1-42 disrupts normal cholinergic neurotransmission (Wang et al., 2000; Nagele et al., 2002; Chen et al., 2006) , further suggesting that Aβ may precipitate cholinergic system dysfunction in AD. 
